<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="630">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351243</url>
  </required_header>
  <id_info>
    <org_study_id>KIN-1901-2001</org_study_id>
    <nct_id>NCT04351243</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)</brief_title>
  <official_title>A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kinevant Sciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roivant Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kinevant Sciences GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled
      study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute
      respiratory distress syndrome (ARDS) secondary to COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gimsilumab is a monoclonal antibody against granulocyte macrophage-colony stimulating factor
      (GM-CSF), which is a myeloid cell growth factor and pro- inflammatory cytokine. Late stages
      of COVID-19 can be marked by a &quot;cytokine storm&quot; and the overactivation of inflammatory
      myeloid cells that infiltrate and damage tissue, such as the lungs. Inhibition of GM-CSF may
      be able to reverse this pathology. The anti-GM-CSF mechanism is distinct from antiviral
      therapeutic mechanisms and may provide synergistic effects when used in combination.

      Study KIN-1901-2001 will consist of a 2-week treatment period (last dose Day 8, if
      administered) and a 22-week follow-up period, for a total study duration of 24 weeks for each
      subject. A total of 270 subjects (135 subjects per arm) who have a confirmed diagnosis of
      COVID-19 with clinical evidence of acute lung injury or ARDS will be entered into the trial.

      Subjects will receive a high dose of gimsilumab on Day 1 and a low dose of gimsilumab on Day
      8, or matching placebo (saline solution) on Day 1 and on Day 8. The Day 8 dose will be
      omitted if the subject is discharged from the hospital or is no longer in need of
      supplemental oxygen or ventilatory support for &gt;48 hours.

      The primary objective of Study KIN-1901-2001 is to evaluate the impact of IV treatment with
      gimsilumab on mortality in subjects with lung injury or ARDS secondary to COVID-19.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of mortality</measure>
    <time_frame>Day 43</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of subjects who are alive and not on mechanical ventilation</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventilator-free days</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>Subjects who die will be assigned &quot;0&quot; ventilator-free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hospital discharge</measure>
    <time_frame>Baseline to Day 43</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Gimsilumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gimsilumab high dose on Day 1 Gimsilumab low dose on Day 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline on Day 1 Normal saline on Day 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gimsilumab</intervention_name>
    <description>Gimsilumab is a fully human monoclonal antibody (mAb).</description>
    <arm_group_label>Gimsilumab</arm_group_label>
    <other_name>KIN-1901</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or non-pregnant female age â‰¥18 years, inclusive

          2. Subject (or legally authorized representative) is able and willing to provide written
             informed consent, which includes compliance with study requirements and restrictions
             listed in the consent form

          3. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other approved
             clinical testing prior to randomization

          4. Radiographic evidence of bilateral infiltrates

          5. Subject requires high-flow oxygen or meets clinical classification for ARDS

          6. Elevated serum CRP or ferritin

          7. Subjects who have been treated with convalescent plasma prior to enrollment are
             eligible if the subject continues to meet all entry criteria at screening

          8. The use of investigational antiviral treatments (e.g., remdesivir, hydroxychloroquine)
             is allowed during the study

        Additional inclusion criteria are detailed in the protocol

        Exclusion Criteria:

          1. Evidence of life-threatening dysrhythmia or cardiac arrest on presentation

          2. Intubated &gt;72 hours

          3. Absolute neutrophil count &lt; 1,000 per mm3

          4. Platelet count &lt; 50,000 per mm3

          5. AST or ALT &gt; 5X upper limit of normal

          6. eGFR &lt;30 mL/min/1.73m2 or requiring hemofiltration or dialysis

          7. History of known anti-GM-CSF autoantibodies or pulmonary alveolar proteinosis

          8. Severe chronic respiratory disease (e.g., COPD, PAH, IPF, ILD) requiring supplemental
             oxygen therapy or mechanical ventilation pre-hospitalization (e.g., prior to COVID-19
             diagnosis)

          9. Known or suspected active and untreated TB, HIV, hepatitis B or C infection

        Additional exclusion criteria are detailed in the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lisa Sherman</last_name>
    <phone>832-592-3466</phone>
    <email>lisa.sherman@roivant.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner University Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marilyn Glassberg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HonorHealth John C. Lincoln Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Gordon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HonorHealth Scottsdale Osborn Medical Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Gordon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Gordon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HonorHealth Scottsdale Shea Medical Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Gordon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Banner University Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Bime, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Ronald Reagan Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tisha Wang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tisha Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Wang, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami Cancer institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guenther Koehne, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Guenther Koehne, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Case, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amy Case, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George M Lyon, MD</last_name>
    </contact>
    <investigator>
      <last_name>George M Lyon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shashi K Bellam, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shashi K Bellam, MD,FCCP, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Jefferson General Hospital</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert J Jeanfreau</last_name>
    </contact>
    <investigator>
      <last_name>Robert J Jeanfreau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Hou, MD</last_name>
    </contact>
    <investigator>
      <last_name>Peter Hou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Botsford General Hospital</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital - Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Sims, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Matthew Sims, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jamaica Hospital Medical Center</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11418</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert I Mendelson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Beth Israel</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ani Cotarlan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai West</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Komal Srivastava, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kusum Mathews, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kusum Mathews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia K Giddings, MD,PhD</last_name>
    </contact>
    <investigator>
      <last_name>Olivia K Giddings, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerard J Criner, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gerard J Criner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Rice, MD</last_name>
    </contact>
    <investigator>
      <last_name>Todd Rice, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Jack &amp; Jane Hamilton Heart and Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Gottlieb, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Gottlieb, MD,PhD</last_name>
    </contact>
    <investigator>
      <last_name>Robert Gottlieb, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White All Saints Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>75061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Gottlieb, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital Affiliated with University of Texas Health Science Center at Houston, McGovern Medical School</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bela Patel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bela Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Medical Center</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Gottlieb, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Medical Center</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Gottlieb, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Medical Center</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Gottlieb, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Medical Campus</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kareem Ahmad, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kareem Ahmad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Granulocyte macrophage-colony stimulating factor (GM-CSF)</keyword>
  <keyword>Immunomodulator</keyword>
  <keyword>Cytokine storm</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>Severe Acute Respiratory Syndrome (SARS)</keyword>
  <keyword>Lung Injury</keyword>
  <keyword>Monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

